
Retired banker from Devon in running challenge hits halfway point
He started the challenge on 16 April in Topsham and is due to end it there after nearly seven months."Reaching the halfway stage is a milestone I could only have dreamed of when I set off 100 days ago," he said."It's overwhelming looking back on what I've achieved."I feel so proud of myself and hope I can inspire others over 60 that you are never too old to attempt the impossible no matter how ridiculous it seems."
The Exeter research team assessed him before his departure and continue to monitor him throughout the challenge, evaluating his calorie intake, blood, oxygen and muscle measurements.
Dr Freyja Haigh, nutritional physiology researcher at the university, said the challenge "gives us a real insight into how this type of endurance affects the body of an older person"."Having reached this point would be an incredible achievement for anyone, but doing it in your 60s is a whole different ball game," she said."What Steve is doing really challenges the stereotypes of ageing and redefines what's possible later in life."It's been such a privilege to work with him so far and I can't wait to see how he gets on in this next stage."The record for running the British coastline is held by Nick Butter, who completed the feat in 128 days at the age of 31.Mr James is the first person aged over 60 to attempt the feat.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
2 hours ago
- Reuters
UK public sector productivity picks up, still lower than before pandemic
LONDON, July 28 (Reuters) - British public sector productivity grew at its fastest annual rate in two years in the first quarter of 2025 but remained lower in outright terms than before the pandemic, official figures showed on Monday. Productivity growth - the main driver of long-term increases in living standards - has been weak across the British economy since the 2008 financial crisis and has slowed more than in similar economies. British public-sector productivity fell especially sharply during the COVID-19 pandemic, when hospitals were unable to carry out many routine treatments. Afterwards it struggled to recover, partly due to industrial action by health workers. Monday's data from Britain's Office for National Statistics showed total public service productivity grew 1.0% in the first quarter of 2025 from a year earlier. That was up from annual growth of 0.8% in the final quarter of 2024 and the fastest since the first quarter of 2023. Public sector productivity growth for 2024 was revised up to 0.1% from a decline of 0.3%, reflecting greater healthcare output than first thought. However, this revision still left the overall productivity 4.2% below its pre-pandemic level while in the health service last year it was nearly 9% lower than in 2019 and similar to its 2012 level. Lower productivity levels effectively mean the public must pay more tax to receive the same services as before - adding to the budget challenge facing Britain's government and a broader sense of public dissatisfaction with major political parties. Measuring public sector productivity is harder than for the private sector as many outputs are tricky to value and it is difficult to track how quality changes. The health service's own estimates show less of a shortfall than the ONS - particularly for quarterly data - due to differences over high-cost drugs, COVID-19 vaccines and how English data is applied to the rest of the United Kingdom. Monday's ONS data are classed as being under development, meaning they are more likely to be revised than main ONS data.


Sky News
3 hours ago
- Sky News
Buyout giant Warburg Pincus snaps up Health Partners stake
One of the world's biggest private equity firms has agreed to acquire a stake in Health Partners Group, a provider of occupational health services to millions of its clients' employees. Sky News understands that Warburg Pincus has struck a deal to partner with the company in a deal valuing it at more than £300m. Health Partners Group was founded in 2016 by chief executive Andrew Noble and chief medical officer Dr Alasdair Emslie. It is principally focused on serving private sector clients, although it does not disclose their identities. In the year to July 31, 2024, it reported revenue of close to £77m and earnings before interest, tax, depreciation and amortisation of £13.6m, according to accounts filed at Companies House. The company says it is now the largest occupational health provider and among the largest non-hospital healthcare providers in Britain. Further details of the transaction with Warburg Pincus, including the size of the stake it had agreed to buy, were unclear on Monday. The deal is said by bankers to value Health Partners at between £300m and £400m. Warburg Pincus has backed similar businesses in other countries, including Quantum Health in the US and Arsipa in Europe.


Reuters
4 hours ago
- Reuters
GSK, China's Jiangsu Hengrui strike $500 million drug-development deal
July 28 (Reuters) - Britain's GSK (GSK.L), opens new tab and China's Jiangsu Hengrui Pharmaceuticals ( opens new tab have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition, the drugmakers said on Monday. The deal comes as GSK focuses on growing its pipeline to offset declining revenues from top drugs and vaccines amid slowing demand and rising competition. It is hoping to reach annual sales of over 40 billion pounds ($53.7 billion) by 2031. Under the deal, GSK will gain an exclusive licence to Hengrui's HRS-9821, which is being studied as a treatment for chronic obstructive pulmonary disease, with an option for 11 other treatments once they have cleared early-stage trials. Hengrui said, opens new tab it could earn up to $12 billion in milestone payments if all options are exercised and targets are met under the GSK deal, which would cover therapy areas such as oncology, immunology, and inflammation. GSK will pay the Chinese firm $500 million upfront. "This deal reflects our strategic investment in programmes that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact," GSK Chief Scientific Officer Tony Wood said. Access to HRS-9821 would support GSK's ambition to treat patients across the widest spectrum of chronic obstructive pulmonary disease, the company said, adding that the drug provides an opportunity for a formulation in the form of a convenient, dry-powder inhaler. GSK's existing therapies for COPD include antibody treatment Nucala, opens new tab and the Trelegy Ellipta inhaler. Shanghai-listed shares of Jiangsu Hengrui climbed 6.6% and its Hong Kong-listed stock jumped 8.5%, outperforming the blue-chip CSI 300 Index's (.CSI300), opens new tab 0.1% fall and the Hang Seng Index's (.HIS), opens new tab 0.3% gain. GSK shares were up 1.5% in London by 0830 GMT, against the 0.2% gain in the wider, blue-chip FTSE 100 (.FTSE), opens new tab index. ($1 = 0.7455 pounds)